Biotechnology

SUNHO BIO-B

SUNHO BIO-B to Release FY2025 Earnings Report on March 27 During-Market BJT

SUNHO BIO-B released FY2025 Q1 earnings on August 29 (BJT), actual revenue HKD 9.103 K, actual EPS HKD 0

SUNHO BIO-B released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue HKD 9.303 K, actual EPS HKD -0.1385

SUNHO BIO-B released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), actual revenue HKD 18.41 K, actual EPS HKD -0.274

SUNHO BIO-B to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Shenghe Biotechnology-B (02898) Releases 2024 Annual Performance, Other Income of 9.485 Million Yuan, Net Loss of 79.965 Million Yuan

SUNHO BIO-B released FY2024 Q3 earnings on March 31 (BJT), actual revenue HKD 0, actual EPS HKD -0.1611

SUNHO BIO-B released FY2024 9 Months earnings on March 31 (BJT), actual revenue HKD 41.01 K, actual EPS HKD -0.5301

SUNHO BIO-B released FY2024 Q4 earnings on March 31 During-Market (BJT), actual revenue HKD 0, actual EPS HKD -0.1546

SUNHO BIO-B released FY2024 earnings on March 31 During-Market BJT, actual revenue HKD 41.13 K, actual EPS HKD -0.6751

SUNHO BIO-B FY2024 Annual Earnings Release Scheduled for March 31, 2025, During-Market BJT

SUNHO BIO-B released FY2024 Q1 earnings on August 30 (BJT), actual revenue HKD 20.59 K, actual EPS HKD -0.1852

Shenghe Biotechnology-B (02898) Releases Mid-term Results for 2024

Shenghebiotech will be listed tomorrow

Biopharmaceutical company Shenghe Biotech - B (02898.HK) announces IPO details

CENTRAL DEV H

FAMEGLOW

ZHONGSHENJIANYE

TJCD

NEW GONOW RV

REALWAY CAPITAL

ZXZN QI-HOUSE

51WORLD

CH CITY INFRA

EASYHOLD GROUP

02898

SUNHO BIO-B has been suspended from trading on the Stock Exchange starting today (1st) at 9:00 AM, until the company publishes an announcement regarding its annual results for 2025

AASTOCKS

SUNHO BIO has suspended trading and published its annual performance for 2025

516500

516930

588250

560600

512290

159849

513120

Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation

Tip Ranks

ChinaAMC CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation

159987

SUNHO BIO-B announced that Ms. Jiang Xiaoling, Executive Director, has been appointed as Chief Executive Officer and Chief Scientific Officer, effective immediately

Yinhua CSI Research Sector 100 ETF

SUNHO BIO appoints CEO and Chief Scientific Officer

Sunho Biologics, Inc. announced that Dr. Yin Liusong will resign as CEO and Chief Scientific Officer effective February 28, 2026, to pursue other opportunities. He stated there is no disagreement with the board, and he will ensure a smooth transition while the company searches for replacements. This leadership change may impact the company's strategic direction. The current analyst rating for Sunho Biologics (HK:2898) is a Hold with a price target of HK$7.00.

Sunho Biologics CEO and Chief Scientific Officer Dr. Yin Liusong to Step Down

02617

02170

As of the time of publication, TRANSTHERA-B rose by 14.13%, SUNHO BIO-B rose by 4.31%, and BASECARE-B rose by 3.65%

Zhitong

TRANSTHERA-B

BASECARE-B

Some Hong Kong pharmaceutical stocks strengthened, with WuXi AppTec rising over 14%

According to the announcement from SUNHO BIO-B, after the recommendation of the audit committee, it has been decided to appoint ZhongHui Anda Certified Public Accountants LLP (ZhongHui Anda) as the new auditor starting from September 16, 2025, to fill the temporary vacancy left by Deloitte's resignation, with a term ending at the conclusion of the company's next annual general meeting

SUNHO BIO-B appoints Zhonghui Anda as the new auditor

According to the Zhitong Finance APP, SUNHO BIO-B announced that Deloitte Touche Tohmatsu Certified Public Accountants (Deloitte) has submitted its resignation letter dated September 9, 2025. Deloitte has resigned as the company's auditor, effective immediately, due to the company's failure to reach an agreement with Deloitte on the audit fees for the consolidated financial statements of the company and its subsidiaries (the Group) for the year ending December 31, 2025

SUNHO BIO-B: Deloitte resigns as the company's auditor

SUNHO BIO-B announced its interim results for the period ending June this year, with other income of RMB 5.035 million, an increase of 182.5% year-on-year. Losses widened to RMB 38.199 million, compared to a loss of RMB 36.077 million in the same period last year; loss per share was RMB 0.25. No dividend was declared

"Performance" SUNHO BIO's half-year loss expanded to 38.2 million yuan

SUNHO BIO-B(02898.HK)

SUNHO BIO has suspended trading and published its annual performance for 2025

Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation

SUNHO BIO appoints CEO and Chief Scientific Officer

Sunho Biologics CEO and Chief Scientific Officer Dr. Yin Liusong to Step Down

Some Hong Kong pharmaceutical stocks strengthened, with WuXi AppTec rising over 14%

SUNHO BIO-B appoints Zhonghui Anda as the new auditor

SUNHO BIO-B: Deloitte resigns as the company's auditor

"Performance" SUNHO BIO's half-year loss expanded to 38.2 million yuan